Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.

Falletta P, Sanchez-Del-Campo L, Chauhan J, Effern M, Kenyon A, Kershaw CJ, Siddaway R, Lisle R, Freter R, Daniels MJ, Lu X, Tüting T, Middleton M, Buffa FM, Willis AE, Pavitt G, Ronai ZA, Sauka-Spengler T, Hölzel M, Goding CR.

Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17.

2.

Lebein, a Snake Venom Disintegrin, Induces Apoptosis in Human Melanoma Cells.

Hammouda MB, Montenegro MF, Sánchez-Del-Campo L, Zakraoui O, Aloui Z, Riahi-Chebbi I, Karoui H, Rodríguez-López JN, Essafi-Benkhadir K.

Toxins (Basel). 2016 Jul 5;8(7). pii: E206. doi: 10.3390/toxins8070206.

3.

MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma.

Ullrich N, Löffek S, Horn S, Ennen M, Sánchez-Del-Campo L, Zhao F, Breitenbuecher F, Davidson I, Singer BB, Schadendorf D, Goding CR, Helfrich I.

Pigment Cell Melanoma Res. 2015 Nov;28(6):736-40. doi: 10.1111/pcmr.12414.

PMID:
26301891
4.

Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development.

Sacilotto N, Monteiro R, Fritzsche M, Becker PW, Sanchez-Del-Campo L, Liu K, Pinheiro P, Ratnayaka I, Davies B, Goding CR, Patient R, Bou-Gharios G, De Val S.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11893-8. doi: 10.1073/pnas.1300805110. Epub 2013 Jul 1.

5.

Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Fernández-Pérez MP, Montenegro MF, Sáez-Ayala M, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

Neoplasia. 2013 Jul;15(7):826-39.

6.

Directed phenotype switching as an effective antimelanoma strategy.

Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN.

Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20.

7.

Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance.

Sáez-Ayala M, Fernández-Pérez MP, Montenegro MF, Sánchez-del-Campo L, Chazarra S, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

Exp Cell Res. 2012 Jun 10;318(10):1146-59. doi: 10.1016/j.yexcr.2012.03.022. Epub 2012 Mar 29.

PMID:
22484375
8.

Comparison of a pair of synthetic tea-catechin-derived epimers: synthesis, antifolate activity, and tyrosinase-mediated activation in melanoma.

Sáez-Ayala M, Sánchez-del-Campo L, Montenegro MF, Chazarra S, Tárraga A, Cabezas-Herrera J, Rodríguez-López JN.

ChemMedChem. 2011 Mar 7;6(3):440-9. doi: 10.1002/cmdc.201000482. Epub 2011 Feb 7.

PMID:
21302360
9.

Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

Sánchez-del-Campo L, Chazarra S, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

J Cell Biochem. 2010 Aug 15;110(6):1399-409. doi: 10.1002/jcb.22656.

PMID:
20564235
10.

Purification and kinetic properties of human recombinant dihydrofolate reductase produced in Bombyx mori chrysalides.

Chazarra S, Aznar-Cervantes S, Sánchez-del-Campo L, Cabezas-Herrera J, Xiaofeng W, Cenis JL, Rodríguez-López JN.

Appl Biochem Biotechnol. 2010 Nov;162(7):1834-46. doi: 10.1007/s12010-010-8961-9.

PMID:
20393885
11.

Binding of natural and synthetic polyphenols to human dihydrofolate reductase.

Sánchez-del-Campo L, Sáez-Ayala M, Chazarra S, Cabezas-Herrera J, Rodríguez-López JN.

Int J Mol Sci. 2009 Dec 18;10(12):5398-410. doi: 10.3390/ijms10125398.

12.

The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate.

Sánchez-del-Campo L, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

Pigment Cell Melanoma Res. 2009 Oct;22(5):588-600. doi: 10.1111/j.1755-148X.2009.00586.x. Epub 2009 Jun 2.

PMID:
19493312
13.

Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.

Sánchez-del-Campo L, Tárraga A, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

Mol Pharm. 2009 May-Jun;6(3):883-94. doi: 10.1021/mp800259k.

PMID:
19358568
14.

Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

Sánchez-del-Campo L, Rodríguez-López JN.

Int J Cancer. 2008 Nov 15;123(10):2446-55. doi: 10.1002/ijc.23813.

15.

Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate.

Sánchez-del-Campo L, Otón F, Tárraga A, Cabezas-Herrera J, Chazarra S, Rodríguez-López JN.

J Med Chem. 2008 Apr 10;51(7):2018-26. doi: 10.1021/jm701346h. Epub 2008 Mar 7.

PMID:
18324763
16.

Effects of folate cycle disruption by the green tea polyphenol epigallocatechin-3-gallate.

Navarro-Perán E, Cabezas-Herrera J, Campo LS, Rodríguez-López JN.

Int J Biochem Cell Biol. 2007;39(12):2215-25. Epub 2007 Jun 26.

PMID:
17683969
17.

Butyrylcholinesterase activity and molecular components in thymus of healthy and merosin-deficient Lama2dy mice.

Sánchez del Campo LF, Nieto-Cerón S, Morote-García JC, Muñoz-Delgado E, Vidal CJ, Campoy FJ.

Neurochem Int. 2007 Feb;50(3):531-9. Epub 2006 Dec 18.

PMID:
17178175
18.

The increased ecto-5'-nucleotidase activity in muscle, heart and liver of laminin alpha2-deficient mice is not caused by an elevation in the mRNA content.

Morote-García JC, Sánchez Del Campo LF, Campoy FJ, Vidal CJ, Muñoz-Delgado E.

Int J Biochem Cell Biol. 2006;38(7):1092-101. Epub 2005 Nov 28.

PMID:
16412684

Supplemental Content

Loading ...
Support Center